Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 580 participants.

Also called NCT06202755

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 580 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06202755
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06202755. Randomized; double masking; primary purpose treatment. Start 2024-03-30 (actual); primary completion 2025-06-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke
Intervention (Drug)
Ticagrelor 90 MG
Intervention (Drug)
Cilostazol 100 MG
Lead sponsor
Kafrelsheikh University (class: other)

Record details

Record id
cardio:ct-nct06202755
Content hash
d28ac78e7a721d5b9b97f35056d71e982d5f3d7ba66e5f6f973aabed8961e802